New Hampshire Trust Has $815,000 Stock Holdings in Novartis AG (NYSE:NVS)

New Hampshire Trust lowered its stake in Novartis AG (NYSE:NVS) by 1.6% during the fourth quarter, Holdings Channel reports. The firm owned 8,374 shares of the company’s stock after selling 137 shares during the period. New Hampshire Trust’s holdings in Novartis were worth $815,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Legacy Investment Solutions LLC acquired a new stake in Novartis during the third quarter worth about $28,000. Fortitude Family Office LLC boosted its position in shares of Novartis by 503.8% during the 3rd quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock worth $37,000 after acquiring an additional 267 shares in the last quarter. Clean Yield Group bought a new position in Novartis in the third quarter valued at approximately $43,000. Brooklyn Investment Group acquired a new position in Novartis during the fourth quarter valued at approximately $55,000. Finally, Versant Capital Management Inc lifted its stake in Novartis by 782.0% during the fourth quarter. Versant Capital Management Inc now owns 785 shares of the company’s stock worth $76,000 after purchasing an additional 696 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Erste Group Bank reissued a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. BMO Capital Markets boosted their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research note on Wednesday, October 30th. Finally, HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Two analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat, Novartis currently has a consensus rating of “Hold” and a consensus price target of $121.50.

Novartis Stock Performance

Shares of NVS stock opened at $97.51 on Tuesday. The firm has a market capitalization of $199.30 billion, a price-to-earnings ratio of 11.32, a PEG ratio of 1.34 and a beta of 0.57. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55. The business’s 50-day moving average price is $100.61 and its 200-day moving average price is $109.01. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The business had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same quarter last year, the business earned $1.74 EPS. Equities research analysts forecast that Novartis AG will post 7.63 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.